ADXN.SW Addex Therapeutics Ltd (SIX) 09 Mar 2026: Earnings due; liquidity and forecast to watch

The ADXN.SW stock moved higher intraday to CHF 0.048 as investors position ahead of Addex Therapeutics Ltd’s earnings release on 09 Mar 2026. Trading volume of 90,001 shares is above average and the stock sits near its year low CHF 0.043. This earnings spotlight focuses on near-term catalysts, cash runway measures, and how results could shift the current intraday price

ADXN.SW stock: intraday price, volume and context

Addex Therapeutics Ltd (ADXN.SW) is trading at CHF 0.048, up 5.22% on the session with a day high CHF 0.050 and day low CHF 0.044. Market cap is roughly CHF 7,543,595.00 and outstanding shares total 150,871,899.
This intraday move comes with volume 90,001, above the 50-day average, showing short-term interest ahead of the earnings announcement.

Earnings set for 09 Mar 2026 and expected drivers

Addex reports after-market on 09 Mar 2026; the company lists the announcement at 16:30 UTC. Investors will watch updates on clinical timelines for dipraglurant and cash guidance.
Clinical readouts, partner updates and guidance on R&D spend typically drive biotech reactions. Pre-earnings positioning often inflates intraday volatility for small-cap biotech names like ADXN.SW

Financials and valuation: what the numbers say

Key ratios show a development-stage biotech profile: EPS -0.06, PE -0.83, and PB 0.95. Book value per share is CHF 0.053 and cash per share is CHF 0.019, supporting a current ratio 2.01.
Revenue per share is negligible and the company posts negative operating cash flow per share CHF -0.014, reflecting R&D spending. These metrics explain the high price-to-sales ratio and wide valuation dispersion versus larger healthcare peers.

Technical, liquidity snapshot and Meyka grade

Technical indicators show muted trend strength: RSI 52.89 and ADX 15.08, suggesting no clear intraday trend. Price averages sit below the 50-day and 200-day means at CHF 0.052 and CHF 0.057 respectively.
Meyka AI rates ADXN.SW with a score out of 100: 66.81 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Grades are model outputs, not guarantees or investment advice.

Analyst view, risks and opportunities for ADXN.SW stock

The main upside stems from positive clinical updates or stronger-than-expected partner commentary. Downside risk includes slower trial progress and cash depletion given small market cap.
Addex’s collaborator relationships partially de-risk programmes, but the stock remains high volatility. Consider tight position sizing and monitor post-earnings liquidity statements for runway clarity.

Outlook and Meyka AI forecast for ADXN.SW

Meyka AI’s forecast model projects CHF 0.050 over the next quarter and CHF 0.0316 over a 12-month horizon. Versus the current price CHF 0.048, the quarterly projection implies +3.31% upside and the 12-month view implies -34.65% downside.
Forecasts are model-based projections and not guarantees. Traders should weigh clinical catalysts, cash per share, and the company’s tiny market cap before acting. For the company page see Addex on Meyka.

Final Thoughts

Key takeaways: ADXN.SW stock is trading at CHF 0.048 ahead of Addex Therapeutics Ltd’s earnings on 09 Mar 2026, with above-average intraday volume 90,001. Financials show typical development-stage biotech metrics: negative EPS -0.06, cash per share CHF 0.019, and book value CHF 0.053. Meyka AI’s forecast model projects a near-term quarterly level at CHF 0.050 and a 12-month projection at CHF 0.0316, implying a short-term upside of 3.31% and a longer-term downside of 34.65% versus the current price.
Meyka’s grade for ADXN.SW is B (66.81) with a HOLD suggestion, reflecting mixed signals from clinical catalysts and tight liquidity. Traders should watch the earnings release for cash-runway commentary and any partner updates. Meyka AI provides this AI-powered market analysis platform view, but forecasts and grades are projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.